Chest Trauma Scoring Systems as Predictors of Morbidity and Mortality in Iraq (NCT06737575) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Chest Trauma Scoring Systems as Predictors of Morbidity and Mortality in Iraq
Iraq190 participantsStarted 2025-04-20
Plain-language summary
This prospective observational study aims to evaluate the effectiveness of chest trauma scoring systems in predicting morbidity and mortality in patients with blunt chest trauma in Iraq. The primary questions it seeks to address are:
How accurately do chest trauma scoring systems predict mortality and critical outcomes such as ICU admission or the need for advanced interventions? How well do these scoring systems stratify patients based on injury severity in a resource-limited setting? Are there any demographic or clinical factors that impact the predictive performance of these scoring systems?
Participants will:
Be assessed using chest trauma scoring systems upon arrival at the emergency department to determine risk levels.
Have demographic and clinical data, including age, gender, injury mechanism, comorbidities, and length of hospital stay, collected to explore potential associations with outcomes.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients diagnosed with blunt chest trauma.
* Patients presenting to the emergency department within 4 hours.
* Patients (or their legal representatives) must provide informed consent to participate in the study.
* Patients who can be assessed using the Chest Trauma Score at the time of arrival (e.g., having stable enough vitals to allow for evaluation).
Exclusion Criteria:
* Patients with penetrating chest trauma (e.g., gunshot or stab wounds), as the Chest Trauma Score is typically used for blunt trauma.
* Patients presenting with chest conditions unrelated to trauma (e.g., pneumonia, COPD exacerbation, or other non-traumatic causes of chest pain or respiratory distress).
* Patients with severe pre-existing comorbidities (e.g., end-stage heart failure, terminal cancer) where trauma is unlikely to be the primary cause of morbidity or mortality.
* Patients with missing or incomplete clinical data, including imaging or vital signs necessary to calculate the CTS accurately.
* Patients who refuse consent or do not agree to the use of their data for research purposes.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
In hospital mortality
Timeframe: In-Hospital Phase (average of 10 days through discharge); Post-Discharge Follow-Up: Day 7, Day 30
2
Accuracy Assessment of the Chest Trauma Score (CTS)